Recombinant AAV Vectors for Treating Proteinopathies in CNS
Summary
The USPTO published patent application US20260091134A1 by Shanghai Vitalgen Biopharma Co., Ltd. covering recombinant adeno-associated viral (rAAV) vectors encoding Progranulin (PGRN) and/or Stathmin-2 (STMN2) for treating proteinopathies in the central nervous system. The application, filed November 26, 2025 (Application No. 19401460), includes codon-optimized coding sequences and viral particle compositions.
What changed
Shanghai Vitalgen Biopharma Co., Ltd. filed patent application US20260091134A1 for recombinant AAV vectors containing PGRN and/or STMN2 nucleotide sequences designed to treat central nervous system proteinopathies. The application covers codon-optimized coding sequences, expression cassettes, vectors, and viral particles comprising the therapeutic sequences. CPC classifications span A61K, C07K, and C12N technical categories related to gene therapy and neurological applications.
This is a published patent application with no compliance obligations or deadlines for third parties. Entities in the biotech or gene therapy space may review the claims to assess potential freedom-to-operate implications or to monitor competitive developments in proteinopathy treatments.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
RECOMBINANT AAV VECTORS FOR TREATING PROTEINOPATHIES IN CENTRAL NERVOUS SYSTEM
Application US20260091134A1 Kind: A1 Apr 02, 2026
Assignee
SHANGHAI VITALGEN BIOPHARMA CO., LTD.
Inventors
Yezheng TAO, Shin-Shay TIAN, Xiaoping ZHAO
Abstract
The present disclosure generally relates to a recombinant adeno-associated viral (rAAV) vector comprising one or two of (a) a nucleotide sequence encoding Progranulin (PGRN), and (b) a nucleotide sequence encoding Stathmin-2 (STMN2), for treating proteinopathies in the central nervous system. Also disclosed are codon-optimized coding sequences of PGRN and/or STMN2, and expression cassettes, vectors, and viral particles comprising the same.
CPC Classifications
A61K 48/005 A61P 25/28 C07K 14/005 C07K 14/475 C12N 15/86 A61K 38/00 C07K 2319/00 C12N 2750/14122 C12N 2750/14143 C12N 2750/14145 C12N 2800/22
Filing Date
2025-11-26
Application No.
19401460
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.